CDG and immune response: From bedside to bench and back

Carlota Pascoal, Rita Francisco, Tiago Ferro, Vanessa dos Reis Ferreira, Jaak Jaeken, Paula A. Videira

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein-attached glycans that mediate cell-cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are congenital disorders of glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterized by an increased propensity to—often life-threatening—infection. Inflammatory and autoimmune complications were found in 7 CDG types. CDG natural history(ies) and the mechanisms behind the immunological anomalies are still poorly understood. However, in some cases, alterations in pathogen recognition and intracellular signaling (eg, TGF-β1, NFAT, and NF-κB) have been suggested. Targeted therapies to restore immune defects are only available for PGM3-CDG and SLC35C1-CDG. Fostering research on glycoimmunology may elucidate the involved pathophysiological mechanisms and open new therapeutic avenues, thus improving CDG patients' quality of life.

Original languageEnglish
JournalJournal of Inherited Metabolic Disease
Publication statusPublished - 1 Jan 2019

Fingerprint

Congenital Disorders of Glycosylation
Glycosylation
Physiological Phenomena
Biological Phenomena
Inborn Genetic Diseases
Foster Home Care
Immune System Diseases
Natural History
Cell Communication
Polysaccharides
Immunity
Quality of Life
Therapeutics
Research

Keywords

  • autoimmune disease
  • congenital disorders of glycosylation
  • immune system
  • immunodeficiency
  • infection
  • inflammation

Cite this

@article{e3908ff3e2054056989fd0c22c3e4ee3,
title = "CDG and immune response: From bedside to bench and back",
abstract = "Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein-attached glycans that mediate cell-cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are congenital disorders of glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterized by an increased propensity to—often life-threatening—infection. Inflammatory and autoimmune complications were found in 7 CDG types. CDG natural history(ies) and the mechanisms behind the immunological anomalies are still poorly understood. However, in some cases, alterations in pathogen recognition and intracellular signaling (eg, TGF-β1, NFAT, and NF-κB) have been suggested. Targeted therapies to restore immune defects are only available for PGM3-CDG and SLC35C1-CDG. Fostering research on glycoimmunology may elucidate the involved pathophysiological mechanisms and open new therapeutic avenues, thus improving CDG patients' quality of life.",
keywords = "autoimmune disease, congenital disorders of glycosylation, immune system, immunodeficiency, infection, inflammation",
author = "Carlota Pascoal and Rita Francisco and Tiago Ferro and {dos Reis Ferreira}, Vanessa and Jaak Jaeken and Videira, {Paula A.}",
year = "2019",
month = "1",
day = "1",
language = "English",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Science Business Media",

}

CDG and immune response: From bedside to bench and back. / Pascoal, Carlota; Francisco, Rita; Ferro, Tiago; dos Reis Ferreira, Vanessa; Jaeken, Jaak; Videira, Paula A.

In: Journal of Inherited Metabolic Disease, 01.01.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - CDG and immune response: From bedside to bench and back

AU - Pascoal, Carlota

AU - Francisco, Rita

AU - Ferro, Tiago

AU - dos Reis Ferreira, Vanessa

AU - Jaeken, Jaak

AU - Videira, Paula A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein-attached glycans that mediate cell-cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are congenital disorders of glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterized by an increased propensity to—often life-threatening—infection. Inflammatory and autoimmune complications were found in 7 CDG types. CDG natural history(ies) and the mechanisms behind the immunological anomalies are still poorly understood. However, in some cases, alterations in pathogen recognition and intracellular signaling (eg, TGF-β1, NFAT, and NF-κB) have been suggested. Targeted therapies to restore immune defects are only available for PGM3-CDG and SLC35C1-CDG. Fostering research on glycoimmunology may elucidate the involved pathophysiological mechanisms and open new therapeutic avenues, thus improving CDG patients' quality of life.

AB - Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein-attached glycans that mediate cell-cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are congenital disorders of glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterized by an increased propensity to—often life-threatening—infection. Inflammatory and autoimmune complications were found in 7 CDG types. CDG natural history(ies) and the mechanisms behind the immunological anomalies are still poorly understood. However, in some cases, alterations in pathogen recognition and intracellular signaling (eg, TGF-β1, NFAT, and NF-κB) have been suggested. Targeted therapies to restore immune defects are only available for PGM3-CDG and SLC35C1-CDG. Fostering research on glycoimmunology may elucidate the involved pathophysiological mechanisms and open new therapeutic avenues, thus improving CDG patients' quality of life.

KW - autoimmune disease

KW - congenital disorders of glycosylation

KW - immune system

KW - immunodeficiency

KW - infection

KW - inflammation

UR - http://www.scopus.com/inward/record.url?scp=85068160845&partnerID=8YFLogxK

M3 - Review article

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

ER -